1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

CMS Approval Will Mark ‘Starting Gate’ For Leqembi Launch For Biogen

 
• By Jessica Merrill

Biogen will likely add sales reps to support Eisai’s US commercial launch of the Alzheimer’s drug early next year when treatment capacity increases.

starting gate
Biogen plans to start investing more in Leqembi after CMS grants reimbursement • Source: Shutterstock

Eisai Co., Ltd. is taking the early lead on the US commercial effort for Leqembi (lecanemab) in Alzheimer’s disease, but the company’s partner,Biogen, Inc., will add reinforcement – as long as the drug has approval for reimbursement from the Centers for Medicare and Medicaid Services (CMS) following full approval by the US Food and Drug Administration.

“The starting gate is really CMS approval,” Biogen CEO Christopher Viehbacher said during the company’s first quarter sales and earnings...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Ionis Targets Ultra-Rare Disease Market With Zilganersen

 
• By Alaric DeArment

The biotech announced positive topline results from its pivotal study in Alexander disease, which has an estimated population of about 300 in the US.

Sanofi’s Pipeline Pressure Continues As Tolebrutinib Trips Near Finish Line

 
• By Manas Mishra

Sanofi’s MS hopeful tolebrutinib hits a regulatory hurdle in the US, renewing pressure on the firm’s pipeline. Analysts hope the delay won’t prove material.

Capsida Is Latest To Have Patient Fatality In Gene Therapy Trial

 
• By Alaric DeArment

The privately owned biotech said it would pause its Phase I/II study of CAP-002 in STXBP1-related disorders after the first patient in the study died.

Lundbeck CEO Looks To The Future With Sharper Commercial Focus

 
• By Kevin Grogan

Charl van Zyl tells Scrip that pipeline is the priority as the company discontinues commercial operations in 27 markets.

More from Therapy Areas

Roche’s evERA Giredestrant Study Hits In All-Comer Breast Cancer Population

 
• By Alexandra Shimmings

The Phase III trial of the SERD has shown a significant benefit in the intent-to-treat and ESR1-mutated populations in post-CDK ER+/HER2- metastatic breast cancer but whether the data will be enough to support an equally broad approval remains to be seen.

Sanofi’s Pipeline Pressure Continues As Tolebrutinib Trips Near Finish Line

 
• By Manas Mishra

Sanofi’s MS hopeful tolebrutinib hits a regulatory hurdle in the US, renewing pressure on the firm’s pipeline. Analysts hope the delay won’t prove material.

Why India Revoked The Entresto Patent And Novartis Abstained From Proceedings

 
• By Anju Ghangurde

India revokes Novartis's patent pertaining to Entresto, upholding the objections of opponents including the Indian Pharmaceutical Alliance on lack of novelty and prior claiming, among others. Novartis decided against participating in the hearings.